Neoadjuvant chemotherapy plus durvalumab, followed by adjuvant durvalumab after cystectomy, led to event-free survival superior to that with neoadjuvant chemotherapy followed by cystectomy alone.
The New England Journal of Medicine: Search Results in Hematology/Oncology
